

Appl. No. 10/502,059
Supplemental Amendment dated: February 2, 2009

REMARKS

This is in response to the Official Action of June 26, 2008 and further to the Amendment of December 29, 2008.

In the Official Action of June 26, 2008, claims 19-32 and 35 were rejected under 35 U.S.C. 112, first paragraph, for allegedly not satisfying the enablement requirement. As noted in the Amendment of December 29, 2008, the claims pending in the application are now directed to methods for reducing the invasion and infection of mammalian cells by pathogenic, intracellular bacteria. Furthermore, the claims no longer recite the "preventing." In this regard, Applicants respectfully submit that the Amendment of December 29, 2008 obviates the rejection.

Nevertheless, Applicants submit herewith evidence that shows the claimed invention is enabled by the present disclosure. In particular, Applicants submit a Declaration by Bernd Stahl. The Declaration reports the results of several experiments that have been conducted that show the administration of cycloglycans in accordance with the claimed invention successfully inhibit the invasion and infection of cells by a variety of pathogenic, intracellular bacteria.

The adhesion of pathogenic organisms to a cell is the first step in an essential prerequisite for infecting a cell. The interaction between pathogenic bacteria and mammalian cells is controlled by a ligand-receptor relationship. The claimed invention is based on the discovery that administering cycloglacans in accordance with the

Appl. No. 10/502,059
Supplemental Amendment dated: February 2, 2009

claimed invention can interfere with this relationship and inhibit pathogenic, intracellular bacteria from invading a mammalian cell.


The Declaration itself shows that the cycloglycans in accordance with the claimed invention can inhibit the invasion and infection of a variety of bacteria, including E.coli, S.typhimurium, and L.monocytogenes. Thus, the claimed invention is enabling for inhibiting the invasion and infection of a variety of pathogenic, intracellular bacteria. In this regard, the Declaration provides further evidence that the disclosure is enabling for claims 36-55.

In particular, Applicants note that new claims 53-55 are directed to a method for reducing the invasion and infection of pathogenic, intracellular bacteria in a subject exposed to the pathogenic, intracellular bacteria. Claim 54 recites that the subject actually has a disease caused by the pathogenic, intracellular bacteria. Claim 55 is dependent on claim 54 and recites that the cycloglycan is administered to an area where particular pathogenic, intracellular bacteria are present. Thus, in this regard, Applicants respectfully submit that claims 53-55 are enabled by the disclosure.

Appl. No. 10/502,059
Supplemental Amendment dated: February 2, 2009

In view of the present Amendment and the Amendment of December 29, 2008,
Applicants respectfully submit that the present application is in condition for allowance
at the time of the next Official Action.

Respectfully submitted,
BACON & THOMAS, PLLC

By: 
Philip A. DuBois
Registration No. 50,696

625 Slaters Lane, Fourth Floor
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080
PAD/amg
Supplemental Amendment.doc
February 2, 2009

Appl. No. 10/502,059

Supplemental Amendment dated: February 2, 2009

APPENDIX

- Declaration Under 37 CFR §1.132 by Bernd Stahl